Company Overview of Lycera Corp.
Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.
2800 Plymouth Road
Ann Arbor, MI 48109
Founded in 2006
Key Executives for Lycera Corp.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Senior Vice President of Corporate Development and Strategy
Senior Vice President of Biology
Compensation as of Fiscal Year 2015.
Lycera Corp. Key Developments
Lycera and Celgene Partner to Advance Development of Immune Modulators
Jun 10 15
Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune-mediated diseases. The partnership will advance development of Lycera's novel pipeline, including first-in-class RORgamma agonists for cancer immunotherapy and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD). As part of the deal, Lycera will provide an $82.5 million upfront cash payment, which comprises an exclusive option for Celgene to license Lycera's portfolio of ex-vivo RORgamma agonist compounds. The deal will also allow Lycera to receive near term payments of an additional $22.5 million associated with the ex-vivo licensing option rights. In addition, the deal provides Celgene exclusive rights to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.
Lycera Begins Phase I Trial of LYC-30937 to Treat Inflammatory Bowel Disease
May 1 15
Lycera announced that the company has started a phase I clinical trial of LYC-30937, an oral gut-directed ATPase modulator, for the treatment of inflammatory bowel disease (IBD). Discovered and developed by Lycera based on technology licensed from the University of Michigan, LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing normal cells. The company maintains full worldwide development and commercial rights of the product. In mid-2016, the company intends to begin clinical trials for its lead immune-oncology product candidate, an agonist of RORgamma, as well as an anti-fibrotic agent, a highly selective ROCK2 (rho-associated kinase II) inhibitor.
Lycera Corp to Present Preclinical Research from its Novel Cancer Immunotherapy Program at the 2015 American Association for Cancer Research Annual Meeting
Mar 19 15
Lycera Corp. announced that the company will present preclinical research from its novel cancer immunotherapy program at the American Association for Cancer Research (AACR) annual meeting, which will take place in Philadelphia, Pennsylvania, April 18-22, 2015. Abbreviated abstract summary: Agents that enhance activation or release suppression of the immune system could form the basis of new treatments for cancer. The receptor RORgamma modulates expression of genes involved in multiple anti-tumor mechanisms. Lycera's program to advance small molecule RORgamma agonists has demonstrated: Select immune cells (Th17 and Tc17) differentiated in the presence of RORgamma agonists exhibit decreased expression of inhibitory molecules, such as PD-1, and increased expression of costimulatory molecules. Th17 and Tc17 cells are reported to mediate potent and durable anti-cancer efficacy. In vitro activation of certain Tc17 cells with RORgamma agonists generates potent effector cells that control the growth of large EG7 tumors when transferred into a preclinical in vivo model. Tumor-infiltrating lymphocytes (TILs) from this model have enhanced survival and decreased PD-1 expression. Oral administration of RORgamma agonists in a preclinical in vivo model significantly inhibits the growth of established, subcutaneous MC38 colon carcinoma tumors. RORgamma agonists also inhibit growth of established, subcutaneous 4T1 mammary carcinoma tumors in an in vivo model. The abstract concluded that, as a transcription modulator, RORgamma agonists increase immune activation and decrease immune suppression. These activities translate into robust anti-tumor effects in syngeneic tumor models and represent a promising approach for the treatment of cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 12, 2015